364 related articles for article (PubMed ID: 33938090)
1. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review.
Jin KT; Du WL; Lan HR; Liu YY; Mao CS; Du JL; Mou XZ
Cancer Sci; 2021 Jul; 112(7):2592-2606. PubMed ID: 33938090
[TBL] [Abstract][Full Text] [Related]
2. Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies.
Horowitz NB; Mohammad I; Moreno-Nieves UY; Koliesnik I; Tran Q; Sunwoo JB
Front Immunol; 2021; 12():648580. PubMed ID: 33968039
[TBL] [Abstract][Full Text] [Related]
3. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
4. Modeling Tumor Immunology and Immunotherapy in Mice.
Buqué A; Galluzzi L
Trends Cancer; 2018 Sep; 4(9):599-601. PubMed ID: 30149876
[TBL] [Abstract][Full Text] [Related]
5. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.
Choi Y; Lee S; Kim K; Kim SH; Chung YJ; Lee C
Exp Mol Med; 2018 Aug; 50(8):1-9. PubMed ID: 30089794
[TBL] [Abstract][Full Text] [Related]
6. The humanized mouse: Emerging translational potential.
Morton JJ; Alzofon N; Jimeno A
Mol Carcinog; 2020 Jul; 59(7):830-838. PubMed ID: 32275343
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
9. Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap.
Morton JJ; Bird G; Refaeli Y; Jimeno A
Cancer Res; 2016 Nov; 76(21):6153-6158. PubMed ID: 27587540
[TBL] [Abstract][Full Text] [Related]
10. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
11. Human Immune System Mice With Autologous Tumor for Modeling Cancer Immunotherapies.
Sun L; Jin CH; Tan S; Liu W; Yang YG
Front Immunol; 2020; 11():591669. PubMed ID: 33133105
[TBL] [Abstract][Full Text] [Related]
12. A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research.
Li Z; Yang X; Zhang Y; Yang X; Cui X; Zhang Y; Gong W; Bai H; Liu N; Tang Z; Guo M; Li K; Zhang T; Wang L; Song X
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475974
[TBL] [Abstract][Full Text] [Related]
13. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
14. Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.
Zloza A; Karolina Palucka A; Coussens LM; Gotwals PJ; Headley MB; Jaffee EM; Lund AW; Sharpe AH; Sznol M; Wainwright DA; Wong KK; Bosenberg MW
J Immunother Cancer; 2017 Sep; 5(1):77. PubMed ID: 28923102
[TBL] [Abstract][Full Text] [Related]
15. Humanized Mice for the Study of Immuno-Oncology.
De La Rochere P; Guil-Luna S; Decaudin D; Azar G; Sidhu SS; Piaggio E
Trends Immunol; 2018 Sep; 39(9):748-763. PubMed ID: 30077656
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
17. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.
Sanmamed MF; Chester C; Melero I; Kohrt H
Ann Oncol; 2016 Jul; 27(7):1190-8. PubMed ID: 26912558
[TBL] [Abstract][Full Text] [Related]
18. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
[TBL] [Abstract][Full Text] [Related]
19. Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy.
Wege AK
BioDrugs; 2018 Jun; 32(3):245-266. PubMed ID: 29589229
[TBL] [Abstract][Full Text] [Related]
20. The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents.
Morillon YM; Sabzevari A; Schlom J; Greiner JW
Anticancer Res; 2020 Oct; 40(10):5329-5341. PubMed ID: 32988851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]